Key Players
Competitive Landscape
Companies competing in vector purification include integrated bioprocess groups, vector-specific media specialists, viral-vector CDMOs and laboratory purification providers.
Investment has shifted since 2025 toward consolidated downstream portfolios and vector-specific chromatography media designed for AAV purification. Rose BioSolutions began operating in May 2026 through GI Partners’ completed acquisition of the Charles River CDMO businesses. Repligen added AAV8 and AAV9 affinity resins plus anion-exchange media in December 2025 for separate capture and polishing steps. Manufacturers now compare serotype coverage, impurity clearance and process-transfer support before equipment price during platform selection.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Rose BioSolutions formed through GI Partners’ completed acquisition of the Charles River CDMO businesses, May 2026 | Gene-therapy developers need one accountable partner from process development through GMP supply | Viral-vector CDMO assets separate from diversified laboratory-services groups | AAV and lentiviral purification development tied to regulated manufacturing |
| Repligen launched AVIPure HiPer AAV8, AAV9 and HiPer QA resins, December 2025 | AAV developers need serotype-specific capture with predictable recovery | Media portfolios separate capsid capture from anion-exchange polishing | Resin screening and scale-up packages for AAV8 and AAV9 |
| Thermo Fisher completed the Solventum purification and filtration acquisition, September 2025: approximately USD 4.0 billion | Bioprocess teams want fewer qualified filtration and separation providers | Large platforms consolidate downstream technologies through acquisitions | Integrated filtration packages for clarification, concentration and buffer exchange |
Danaher and Merck compete through broad downstream technologies while Sartorius, Lonza and FUJIFILM Biotechnologies add chromatography or regulated vector manufacturing without a comparable purification-specific event since January 2025.
Source: Future Market Insights, Vector Purification and Viral Vector Development Market Reports, 2026-2036.
Danaher, Merck, Thermo Fisher, Sartorius and Repligen cover centrifugation, chromatography, filtration and analytical support while Lonza, FUJIFILM Biotechnologies and Rose BioSolutions connect downstream development with GMP manufacture.
Which companies combine vector-specific media with broader downstream systems?
Merck and Thermo Fisher combine chromatography with filtration across viral-vector downstream processing while Repligen concentrates on AAV8 and AAV9 affinity capture plus anion-exchange polishing media.
Which companies document full-capsid or serotype-specific purification?
Repligen documents serotype-specific AAV8 and AAV9 affinity media while Sartorius documents monolith chromatography for capsid separation and Danaher supports density-gradient preparation through Beckman Coulter.
Which companies connect purification development with GMP vector manufacture?
Lonza, FUJIFILM Biotechnologies and Rose BioSolutions connect downstream process development with regulated viral-vector manufacturing for AAV and related vector programs.
Which providers cover research-scale and commercial-scale workflows?
Danaher supports research-scale gradient preparation while Merck, Thermo Fisher, Sartorius and Repligen supply production technologies that extend into GMP manufacture through Lonza, FUJIFILM Biotechnologies and Rose BioSolutions.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Danaher Corporation | Global | Cytiva chromatography and filtration with Beckman Coulter density-gradient preparation for research workflows. |
| Merck KGaA | Global | Viral-vector downstream processing through chromatography, ultrafiltration and sterile filtration. |
| Thermo Fisher Scientific Inc. | Global | AAV capture and polishing media with filtration and separation technologies. |
| Sartorius AG | Global | Monolith chromatography for AAV capture and full-capsid separation. |
| Lonza Group AG | North America, Europe and Asia | Viral-vector process development and cGMP manufacturing from 50 liters to 2,000 liters. |
| FUJIFILM Biotechnologies | North America and Europe | AAV platform development with downstream processing and cGMP manufacturing. |
| Repligen Corporation | Global | AAV8 and AAV9 affinity resins, anion-exchange media, filtration and chromatography systems. |
| Rose BioSolutions | North America and Europe | AAV and lentiviral process development with affinity chromatography, filtration and GMP manufacturing. |
Research Methodology
The companies here show how the vector purification market is structured without presenting an exhaustive ranking. A company appears only where current official evidence shows it supplies purification technology or regulated downstream support for AAV, lentiviral, adenoviral or retroviral vectors. Evidence comes from official company websites, filings, acquisition announcements, press releases and technical records that document current market activity. Capabilities apply to the named company or site rather than the wider corporate group throughout this comparison. Technology shares are FMI estimates, with AAV vectors at 46.0% and chromatography at 42.0% in 2026 respectively.
